# Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

> **NCT01335074** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Philipps University Marburg**

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Temsirolimus + Sorafenib

## Key facts

- **NCT ID:** NCT01335074
- **Lead sponsor:** Philipps University Marburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-04
- **Primary completion:** 2013-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01335074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01335074, "Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01335074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*